Novel Approaches in Waldenstrom Macroglobulinemia. Hematology/oncology clinics of North America Spinner, M. A., Varma, G., Advani, R. H. 2018; 32 (5): 875–90


Recent advances in the understanding of Waldenstrom macroglobulinemia (WM) biology have paved the way for development of a plethora of novel therapeutic strategies. The success of ibrutinib in WM has shifted treatment paradigms away from conventional chemoimmunotherapy approaches. Recognition of high-risk genomic subgroups as well as mechanisms of acquired resistance to ibrutinib have led to targeting of additional pathways. In this article, the authors review ongoing and emerging trials of novel therapies in WM that target the B-cell receptor pathway beyond ibrutinib, toll-like receptor pathway, chemokine signaling, apoptotic pathway, chromatin remodeling, protein transport, the immune microenvironment, and CD19-directed immunotherapy.

View details for PubMedID 30190025